Internal Medicine, Hematology & Oncology · Detroit, MI
NPI
1881953925
Since 2012
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
5
Medicare group memberships
Hospitals
5
Hospital affiliations
4201 Saint Antoine St, Suite 2e
Detroit, MI, 48201
Phone (313) 745-4832
Groups this clinician bills Medicare through
Medicare paid, 2024
$72K
912 services
Medicare patients, 2024
289
Average age 73
Drug cost, 2024
$10.0M
3,097 prescriptions
Company payments, 2025
$893
From 28 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Muhammad Usman was code 99214 (office e&m - established), 550 times for 222 patients. In total Muhammad Usman billed 912 services in 12 codes, and Medicare paid $72K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-11-24.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 550 | 222 | $67.50 | $37K |
| 99215 Office E&M - Established | Facility | 180 | 78 | $110.04 | $20K |
| 99233 Hospital E&M - Subsequent | Facility | 34 | 19 | $91.43 | $3,109 |
| 99204 Office E&M - New | Facility | 32 | 32 | $87.94 | $2,814 |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 28 | 20 | $23.31 | $653 |
| 99205 Office E&M - New | Facility | 21 | 21 | $127.68 | $2,681 |
| 99235 Observation Care | Facility | 20 | 11 | $122.92 | $2,458 |
| 99214 Office E&M - Established | Office | 15 | 12 | $93.01 | $1,395 |
| 99232 Hospital E&M - Subsequent | Facility | 11 | 11 | $60.44 | $665 |
By year: 2022 $63K for 823 services; 2023 $59K for 765 services; 2024 $72K for 912 services.
Medicare prescription drug claims, 2024
In 2024, the drug Muhammad Usman prescribed most often to Medicare patients was Acyclovir, with 323 prescriptions and refills. In total Muhammad Usman wrote 3,097 Medicare prescriptions that cost $10.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Acyclovir Generic | 323 | 427 | 69 | $4,764 |
| Eliquis Apixaban | 251 | 278 | 50 | $153K |
| Venclexta Venetoclax | 206 | 206 | 35 | $1.7M |
| Pantoprazole Sodium Generic | 115 | 149 | 28 | $1,463 |
| Revlimid Lenalidomide | 115 | 115 | 21 | $1.7M |
| Hydroxyurea Generic | 108 | 193 | 30 | $2,770 |
| Levofloxacin Generic | 88 | 90 | 34 | $612 |
| Lenalidomide Generic | 82 | 82 | 18 | $926K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 74 | 74 | 25 | $1,589 |
| Levothyroxine Sodium Generic | 71 | 93 | 18 | $512 |
| Dexamethasone Generic | 64 | 78 | 28 | $1,300 |
| Ondansetron Hcl Generic | 59 | 59 | 26 | $402 |
| Imatinib Mesylate Generic | 57 | 57 | Under 11 | $8,696 |
| Xarelto Rivaroxaban | 57 | 73 | Under 11 | $40K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 53 | 70 | 15 | $132 |
Brand drugs: 1,053 claims; generic drugs: 2,031 claims; opioid claims: 210.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Muhammad Usman $893 ($893 in general payments such as food, travel and fees) from 28 companies. The largest payer was Novartis Pharmaceuticals Corporation with $128.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 6 | $128 |
| Janssen Biotech, Inc. JNJ | 3 | $71.04 |
| Merck Sharp & Dohme LLC MRK | 2 | $56.23 |
| BeOne Medicines USA, Inc. ONC | 2 | $54.69 |
| Incyte Corporation INCY | 2 | $53.96 |
| Celgene Corporation BMY | 2 | $42.01 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $35.83 |
| Sirtex Medical Inc | 1 | $32.52 |
| Recordati_rare_diseases_inc. | 1 | $30.54 |
| Jazz Pharmaceuticals Inc. JAZZ | 1 | $27.79 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.